Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could reveal brain tumor aggression without surgery

NCT ID NCT00850278

Diagnosis Sponsor: University Hospital, Caen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a special PET scan tracer called FLT in 50 adults with brain tumors (gliomas or metastases). The goal was to see if FLT-PET can measure how fast tumor cells are growing, which could help doctors diagnose and predict tumor behavior better than current scans like MRI or MET-PET. Participants received FLT-PET, MET-PET, and MRI before surgery, and results were compared with lab tests and survival data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FLT (a radioactive tracer for PET imaging)
What this could lead to
If successful, FLT-PET could become a better way to see how aggressive a brain tumor is without surgery, helping doctors plan treatment more accurately.
What could go wrong
This is a small, early imaging study (50 people) that only looks at whether the scan works, not whether it improves outcomes. The tracer may not be better than existing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Start date

Oct 2008

Finished

Jul 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults aged between 18 and 70 years * must have operable grade II, III or IV glioma, recurrent high grade glioma or brain metastases * KPS \>= 70% * must have the understanding and ability to sign an informed consent document * must have adequate liver and kidney function * be male or non-pregnant, non-lactating females * patients who are fertile must agree to use an effective method of contraception during participation in the study * the following laboratory results : absolute neutrophil count \>= 1500 cells/µl, platelet count \>= 100000 cells/µl, SGOT \<= 2.5 x ULN, serum creatinine \<= 1.5 x ULN. Exclusion Criteria: * contraindication to surgery * concomitant radio-, chemo-, or immunotherapy * history of significant dementia * known diagnosis of Human Immunodeficiency Virus (HIV) infection * patient with hepatitis B or C

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm cancer glioma malignant glioma metastatic malignant neoplasm in the brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumors Cancer

Contacts and locations

Locations

  • Caen University Hospital

    Caen, 14033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.